Cargando…
Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478
Autores principales: | Panjideh, Hossein, Niesler, Nicole, Weng, Alexander, Fuchs, Hendrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9608844/ https://www.ncbi.nlm.nih.gov/pubmed/36287991 http://dx.doi.org/10.3390/toxins14100703 |
Ejemplares similares
-
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861
por: Panjideh, Hossein, et al.
Publicado: (2022) -
Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861
por: Zarinwall, Ajmal, et al.
Publicado: (2021) -
Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861
por: Bhargava, Cheenu, et al.
Publicado: (2017) -
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
por: Fuchs, Hendrik, et al.
Publicado: (2017) -
Dianthin and Its Potential in Targeted Tumor Therapies
por: Fuchs, Hendrik
Publicado: (2019)